Free Trial

Catherine Novack Analyst Performance

Analyst at UBS Group

Catherine Novack is a stock analyst at UBS Group focused in the medical sector, covering 11 publicly traded companies. Over the past year, Catherine Novack has issued 9 stock ratings, including buy and hold recommendations. While full access to Catherine Novack's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Catherine Novack's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
12 Last 1 Years
Buy Recommendations
75.00% 9 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%9 ratings
Hold25.0%3 ratings
Sell0.0%0 ratings

Out of 12 total stock ratings issued by Catherine Novack at UBS Group, the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
11 companies

Catherine Novack, an analyst at UBS Group, currently covers 11 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
10 companies
90.9%
Manufacturing
1 company
9.1%

Catherine Novack of UBS Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
54.5%
MED - DRUGS
3 companies
27.3%
PHARMACEUTICAL PREPARATIONS
1 company
9.1%
MED PRODUCTS
1 company
9.1%

Catherine Novack's Ratings History at UBS Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4/17/2026Reiterated Rating$7.69$30.00Buy
iBio, Inc. stock logo
IBIO
iBio
3/3/2026Initiated Coverage$2.69$7.00Buy
Septerna, Inc. stock logo
SEPN
Septerna
12/23/2025Initiated Coverage$29.47$43.00Buy
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
12/15/2025Reiterated Rating$87.89$143.00Buy
Korro Bio, Inc. stock logo
KRRO
Korro Bio
11/14/2025Downgrade$6.50Hold
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
10/1/2025Initiated Coverage$13.29$33.00Buy
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
6/26/2025Initiated Coverage$10.42$30.00Buy
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
6/25/2025Lower Price Target$9.25$29.00Buy
Femasys Inc. stock logo
FEMY
Femasys
5/13/2025Lower Price Target$1.10$6.00Buy
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
4/30/2025Reiterated Rating$7.91$7.00Hold
Rallybio Corporation stock logo
RLYB
Rallybio
4/15/2025Reiterated Rating$0.27Hold
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
3/25/2025Initiated Coverage$27.87$45.00Buy